Cite
Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy
MLA
Mottolese, Marcella, et al. “Role of P53 and BCL-2 in High-Risk Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy.” Journal of Cancer Research and Clinical Oncology, vol. 126, no. 12, Nov. 2000, pp. 722–29. EBSCOhost, https://doi.org/10.1007/PL00008478.
APA
Mottolese, M., Benevolo, M., Del Monte, G., Buglioni, S., Papaldo, P., Nisticò, C., Di Filippo, F., Vasselli, S., Vici, P., & Botti, C. (2000). Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Journal of Cancer Research and Clinical Oncology, 126(12), 722–729. https://doi.org/10.1007/PL00008478
Chicago
Mottolese, Marcella, Maria Benevolo, Girolamo Del Monte, Simonetta Buglioni, Paola Papaldo, Cecilia Nisticò, Franco Di Filippo, Stefania Vasselli, Patrizia Vici, and Claudio Botti. 2000. “Role of P53 and BCL-2 in High-Risk Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy.” Journal of Cancer Research and Clinical Oncology 126 (12): 722–29. doi:10.1007/PL00008478.